Biogen stock: Lecanemab data show benefit in alpha-synuclein group
Published on 11/20/2026 at 22:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSLecanemab Findings Add Clinical Context
- Biogen and Eisai presented Clarity AD cerebrospinal-fluid subgroup findings at the CTAD 2026 conference.
- The exploratory alpha-synuclein-positive group showed a 41% lower decline on the CDR-SB measure versus placebo at 18 months.
- The analysis supports continued attention on lecanemab's potential role in early Alzheimer's disease.
Biogen and Eisai said on November 19 that a Clarity AD analysis presented at the 19th Clinical Trials on Alzheimer’s Disease conference showed slower clinical decline with lecanemab in an alpha-synuclein-positive subgroup of people with early Alzheimer’s disease. The findings were published in a Biogen investor release.
Subgroup Results From CTAD
The post hoc analysis examined cerebrospinal-fluid samples from the Clarity AD study. Among 400 amyloid-positive participants with available alpha-synuclein results, the reduction in decline versus placebo at 18 months was 26% on the CDR-SB measure.
In the exploratory alpha-synuclein-positive group of 82 participants, the reduction in decline reached 41% on CDR-SB. The corresponding reductions were 43% on ADAS-Cog14 and 43% on ADCS MCI-ADL, according to the company.
Biogen stock traded at 227.60 euros on Lang & Schwarz at 10:10 p.m. CET on Friday, November 20, 2026.
Biogen Inc. at a Glance
- Company: Biogen Inc.
- ISIN: US09062X1037
- Ticker: BIIB
- Home exchange: Nasdaq
- Lang & Schwarz price: 227.60 euros on November 20, 2026, at 10:10 p.m. CET
The S&P 500 provides the broader US market context for biotechnology shares.
